

Andre Larente from DIAGNOS on Deal with World's Largest Eyecare Retailer EssilorLuxottica

written by InvestorNews | December 14, 2023

InvestorNews host Tracy Weslosky recently conducted an insightful interview with André Larente, President and Director of [DIAGNOS Inc.](#) (TSXV: ADK | OTCQB: DGNOF), to discuss the company's exclusive [distribution agreement](#) with EssilorLuxottica. DIAGNOS, known for its pioneering FLAIRE platform based on Artificial Intelligence (AI), has solidified its position as a leading provider of retinal analysis technology through this partnership. This agreement, announced on December 11th, is a significant milestone for DIAGNOS, signaling its growing influence in the AI and healthcare technical services sector.

During the interview, Larente highlighted the capabilities of DIAGNOS' AI-powered retinal image analysis technology, which has been acclaimed for its role in the early detection of various eye conditions. This breakthrough technology not only enhances the quality of eye health care but also significantly impacts patient lives positively. The partnership with EssilorLuxottica, a global leader in vision care with an \$87Bn market cap, is set for an initial three-year term with potential for renewal.

Under the agreement, DIAGNOS will be compensated on a per patient exam basis across EssilorLuxottica's client network. Larente expressed his pride in the partnership, emphasizing the pivotal role it plays in DIAGNOS' mission to broaden the accessibility of its retinal analysis technology. This

collaboration is expected to contribute significantly to visual health in Canada and potentially the USA. Both DIAGNOS and EssilorLuxottica are committed to advancing eye health and technology, with a focus on offering innovative solutions to optometrists that will transform the early detection and quality of eye care in the region.

In summary, DIAGNOS' exclusive distribution agreement with EssilorLuxottica marks a key development in its journey, reinforcing its commitment to revolutionizing eye health care through advanced AI-based technologies. This collaboration is set to make a profound impact on the early detection and treatment of eye conditions, benefiting a wide range of patients and healthcare providers.

To access the complete interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

About DIAGNOS Inc.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

To learn more about DIAGNOS Inc., [click here](#)

Disclaimer: *DIAGNOS Inc. is an advertorial member of InvestorNews Inc.*

This interview, which was produced by InvestorNews Inc.

(“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its

securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on [SedarPlus.ca](https://www.sedarplus.ca) and to carry out independent investigations in order to determine their interest in investing in the Company.

Predictmedix is starting to commercialize as AI health screening & monitoring takes off

written by InvestorNews | December 14, 2023

Health screening is big business these days. The latest way is using Artificial Intelligence (AI) to mass screen and/or monitor for impairment and various disease states, including COVID-19.

One company is now starting to commercialize their technology, winning contracts and forming distribution partners all around the globe. That company is [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF).

The global market size for AI in healthcare in 2017 was US\$1.4b and is forecast to rise to reach [US\\$28b](#) by 2025, for an

approximate 20 fold increase in just 8 years. Healthcare screening and monitoring using AI can play a key role.

The global market for artificial intelligence (AI) in healthcare is forecast to take off



[Source](#)

Predictmedix has developed leading disruptive AI technology in impairment detection and healthcare screenings. Their AI powered products use facial, thermal, video and audio recognition technologies to determine when individuals are suffering from infectious disease, are drug or alcohol impaired, or have a mental illness. The Predictmedix screening devices are backed up by a remote patient monitoring platform.



[Source](#)

Predictmedix's latest achievements to commercialize their screening AI technology

- [October 1, 2020](#) – Partnered with Versus Systems to develop tools for clinical trials, in particular on-site monitoring to ensure human subject protection, data integrity, and quality. The news release [states](#): “This will allow Predictmedix to enter a new industry vertical of clinical trials which is a \$40 billion market opportunity as estimated by Fortune Business Insights.”
- [September 3, 2020](#) – Predictmedix Inc. and Juiceworks Exhibits provide safe entry solutions to facility managers at IFMA World Workplace in Texas.
- [August 17, 2020](#) – Predictmedix Inc. and Juiceworks Exhibits announce COVID-19 technology deployments in North

America.

- [August 12, 2020](#) – Deployment of Impairment Screening along with COVID-19 symptom screening technology at Indian Oil Corporation.
- [July 7, 2020](#) – Sales/distributor 1 year contract with Taurus Medical in the United Kingdom. Taurus Medical manufacture and market over 1,500 products for the diagnosis, treatment and monitoring of respiratory conditions. They are a supplier for the UK National Health Service. Taurus is offering Predictmedix COVID-19 mass screening entry modules to the healthcare, retail, and the entertainment sector in the UK.
- [June 26, 2020](#) – Teamed up with Tech Mahindra who will resell Predictmedix to their global client base. Tech Mahindra is a \$4.9 billion dollar company owned by Mahindra Group. Tech Mahindra is operational across 90 countries, helping 973 global customers including Fortune 500 companies.

Regarding the Indian Oil Corporation contract Predictmedix [state](#):

“The deployment of our COVID-19 screening and impairment technology at IOCL which is a fortune 500 company marks our entry into the Oil & Gas sector which is one of the largest industrial sectors and it further highlights the market need for the suite of technologies developed by Predictmedix.”

Now that’s a very busy past 5 months. The model of using well known brands (Juiceworks Exhibits, Taurus Medical, Tech Mahindra) with large distribution networks should make for a faster and more successful commercialization. Product deployment at large corporations such as Indian Oil Corporation show solid early demand for the Predictmedix product.

Predictmedix operates under a SaaS model. Clients pay a monthly

fee based on tiered volume of screenings or by number of device feeds. Both pricing options provide Predictmedix with recurring monthly revenue and multi-year contracts.

Right now as COVID-19 cases approach [40 million](#) (and 1.2 million deaths) it certainly looks like there is a massive potential market for Predictmedix's COVID-19 Safe Entry Solutions. This could be the product that rapidly launches Predictmedix into the AI health screening market. You can read more on that [here](#).

Predictmedix current market cap is C\$58m. The Company looks to have plenty of growth opportunities ahead as it strives to capture a share of the forecast [US\\$28b](#) AI healthcare market by 2025.

Further learning

- [Predictmedix's Dr. Rahul Kushwah on using AI to solve real world problems](#)